Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Effectiveness and Safety of ALGRX 3268 in Pediatric Subjects.
NCT00146185 is registered in ClinicalTrials.gov with AlgoRx Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Effectiveness and Safety of ALGRX 3268 in Pediatric Subjects.
- Lead sponsor
- AlgoRx Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 28, 2005
- Completion date
- July 31, 2005
- Enrollment
- 504
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.